Recursion Pharmaceuticals Inc Cash Flow Conversion Efficiency
Recursion Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Recursion Pharmaceuticals Inc (RXRX) has a cash flow conversion efficiency ratio of -0.116x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-105.95 Million) by net assets ($915.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Recursion Pharmaceuticals Inc (2019–2025)
Cash flow conversion efficiency of Recursion Pharmaceuticals Inc from 2019 to 2025. This chart illustrates how Recursion Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View RXRX stock price for real-time trading data and today's change.
Recursion Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Recursion Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Recursion Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Recursion Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Recursion Pharmaceuticals Inc (RXRX) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dunelm Group plc
F:DFQ
|
0.329x |
|
Southchip Semiconductor Technology (Shanghai) Co. Ltd. A
SHG:688484
|
-0.024x |
|
Lily Group Co Ltd
SHG:603823
|
0.020x |
|
Ceconomy AG
XETRA:CEC
|
0.401x |
|
Shenzhen Sed Industry Co Ltd
SHE:000032
|
-0.015x |
|
Entra ASA
OL:ENTRA
|
0.006x |
|
Newmark Group Inc
NASDAQ:NMRK
|
0.207x |
|
OFG Bancorp
NYSE:OFG
|
0.028x |
Annual Cash Flow Conversion Efficiency for Recursion Pharmaceuticals Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Recursion Pharmaceuticals Inc from 2019 to 2025. Review RXRX cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.13 Billion | $-371.81 Million | -0.329x | +5.28% |
| 2024-12-31 | $1.03 Billion | $-359.17 Million | -0.347x | +44.10% |
| 2023-12-31 | $463.44 Million | $-287.78 Million | -0.621x | -261.18% |
| 2022-12-31 | $485.81 Million | $-83.52 Million | -0.172x | +41.15% |
| 2021-12-31 | $542.94 Million | $-158.61 Million | -0.292x | -232.75% |
| 2020-12-31 | $-206.29 Million | $-45.40 Million | 0.220x | -52.06% |
| 2019-12-31 | $-124.27 Million | $-57.04 Million | 0.459x | -- |
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenom… Read more